Vitamins, Breastmilk HIV Shedding, and Child Health
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to analyze stored samples and data collected during the conduct of the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257). The aims are to examine the effect of vitamin supplementation on HIV infected women during pregnancy on a number of parameters in breastmilk.
Condition | Intervention | Phase |
---|---|---|
Maternal and Child Health Outcomes |
Dietary Supplement: Vitamin A alone Dietary Supplement: Multivitamins excluding vitamin A Dietary Supplement: multivitamins including vitamin A Other: Placebo |
Phase 3 |
Study Type: | Observational |
Study Design: | Observational Model: Cohort Time Perspective: Prospective |
Official Title: | Vitamins, Breastmilk HIV Shedding, and Child Health |
- cell-free viral load and/or cell-associated proviral load in breast milk [ Time Frame: Delivery, 3 months, and 6 months after delivery ] [ Designated as safety issue: Yes ]
- concentration of vitamins A, B12, and E in breast milk [ Time Frame: Delivery, 3 months, and 6 months post-delivery ] [ Designated as safety issue: No ]
- subclinical mastitis [ Time Frame: Delivery, 3 months, and 6 months after delivery ] [ Designated as safety issue: No ]
- post-natal mother-to-child transmission of HIV [ Time Frame: Delivery, 3 months, and 6 months post-delivery ] [ Designated as safety issue: No ]
- infant mortality and morbidity from diarrhea [ Time Frame: Delivery, 3 months and 6 months after delivery ] [ Designated as safety issue: No ]
- a.) CCR5 expression in differentiating monocytes and differentiated monocyte-derived macrophages [ Time Frame: N/A (in vitro experiment) ] [ Designated as safety issue: No ]
- HIV-1 replication in differentiating monocytes acutely infected with a subtype C HIV-1 clone, differentiated non-dividing MDMs acutely infected with the HIV-1 MJ4 clone, and differentiated non-dividing MDMs chronically infected with the HIV-1 MJ4 clone. [ Time Frame: N/A (in vitro experiment) ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Breast milk samples collected from breast at delivery and at 3 month intervals thereafter.
Enrollment: | 771 |
Study Start Date: | September 2004 |
Study Completion Date: | August 2007 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Vitamin A
Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
|
Dietary Supplement: Vitamin A alone
30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
|
No Vitamin A
Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
|
Dietary Supplement: Multivitamins excluding vitamin A
30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
Dietary Supplement: multivitamins including vitamin A
20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
Other: Placebo
Placebo pill taken orally once per day during pregnancy and lactation
|
Multivitamins
Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
|
Dietary Supplement: Vitamin A alone
30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
Dietary Supplement: Multivitamins excluding vitamin A
30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
Dietary Supplement: multivitamins including vitamin A
20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
|
No Multivitamins
Participants from the parent study who had been randomized to vitamin A alone or placebo
|
Dietary Supplement: Vitamin A alone
30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
Other: Placebo
Placebo pill taken orally once per day during pregnancy and lactation
|
Detailed Description:
The purpose of this study is to analyze stored samples and data collected during the conduct of the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257). The aims are to examine the effect of vitamin supplementation on HIV infected women during pregnancy
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
The data and samples used in this study are from HIV-infected pregnant women who participated in the "Trial of Vitamins in HIV Transmission and Progression". Between 1995 and 1997, 1,078 African, HIV positive women who were between gestatopm weeks 12 and 27 were recruited. They were followed until August 2003. This study was conducte among 771 of these women, for whom breast milk samples were available at delivery. There were no differences in baseline characteristics between this subset and the originally randomized group of 1,069.
This study is analyzing samples previously collected from the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257).
The inclusion criteria in this study was:
- HIV infected women presenting to antenatal care between 12 and 27 weeks of gestation
United States, Massachusetts | |
Harvard School of Public Health | |
Boston, Massachusetts, United States, 02115 |
Principal Investigator: | Eduardo Villamor, MD,DrPH | Harvard School of Public Health |
No publications provided by Harvard School of Public Health
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Eduardo Villamor, MD, DrPH, Harvard School of Public Health |
ClinicalTrials.gov Identifier: | NCT00197756 History of Changes |
Other Study ID Numbers: | HD45134 |
Study First Received: | September 12, 2005 |
Last Updated: | August 20, 2009 |
Health Authority: | United States: Federal Government Tanzania: Ministry of Health |
Keywords provided by Harvard School of Public Health:
HIV Breastfeeding Vitamins Tanzania Children |
Additional relevant MeSH terms:
Vitamin A Vitamins Retinol palmitate Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions |
Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Anticarcinogenic Agents Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 16, 2012